BARBIERI, Elena
 Distribuzione geografica
Continente #
NA - Nord America 4.598
EU - Europa 2.375
AS - Asia 2.060
SA - Sud America 312
AF - Africa 51
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.409
Nazione #
US - Stati Uniti d'America 4.541
SG - Singapore 610
IT - Italia 581
CN - Cina 522
GB - Regno Unito 500
IE - Irlanda 346
HK - Hong Kong 260
BR - Brasile 232
SE - Svezia 217
VN - Vietnam 215
DE - Germania 211
BD - Bangladesh 114
FI - Finlandia 110
UA - Ucraina 105
RU - Federazione Russa 92
FR - Francia 66
IN - India 63
TR - Turchia 51
KR - Corea 45
BG - Bulgaria 37
ID - Indonesia 33
CA - Canada 31
AR - Argentina 23
IQ - Iraq 20
NL - Olanda 20
IR - Iran 18
ZA - Sudafrica 18
PL - Polonia 15
MX - Messico 14
ES - Italia 13
AE - Emirati Arabi Uniti 12
JP - Giappone 12
VE - Venezuela 12
CO - Colombia 11
EC - Ecuador 11
CL - Cile 10
MY - Malesia 10
PK - Pakistan 10
AZ - Azerbaigian 9
AU - Australia 8
TW - Taiwan 7
UZ - Uzbekistan 7
AT - Austria 6
BE - Belgio 6
EG - Egitto 6
NG - Nigeria 6
PY - Paraguay 6
CZ - Repubblica Ceca 5
JO - Giordania 5
LT - Lituania 5
MT - Malta 5
PH - Filippine 5
AL - Albania 4
DO - Repubblica Dominicana 4
KE - Kenya 4
MA - Marocco 4
NP - Nepal 4
PT - Portogallo 4
SA - Arabia Saudita 4
SI - Slovenia 4
TH - Thailandia 4
UY - Uruguay 4
CH - Svizzera 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
HN - Honduras 3
IL - Israele 3
LB - Libano 3
LV - Lettonia 3
AO - Angola 2
BO - Bolivia 2
BY - Bielorussia 2
EE - Estonia 2
ET - Etiopia 2
JM - Giamaica 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
GA - Gabon 1
HU - Ungheria 1
KZ - Kazakistan 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NO - Norvegia 1
PE - Perù 1
PR - Porto Rico 1
Totale 9.406
Città #
Santa Clara 435
Singapore 417
Ashburn 396
Dublin 346
Fairfield 322
Southend 298
Chandler 265
Hong Kong 256
Woodbridge 225
San Jose 223
Houston 185
Jacksonville 176
Dearborn 168
Ann Arbor 162
Beijing 154
Nyköping 131
Chicago 123
Wilmington 120
Seattle 119
Cambridge 107
Los Angeles 99
Council Bluffs 94
London 88
Hefei 82
Helsinki 79
New York 77
The Dalles 69
Ho Chi Minh City 64
Modena 57
Dallas 50
Hanoi 46
Seoul 44
Munich 43
Milan 39
Moscow 37
Princeton 37
Rome 37
Salt Lake City 37
Sofia 35
Eugene 32
Izmir 30
Lauterbourg 30
Shanghai 29
Jakarta 27
São Paulo 27
Buffalo 26
San Diego 26
Tampa 26
Elk Grove Village 25
Bremen 24
Bologna 22
Dong Ket 22
Orem 22
Columbus 21
Fremont 16
Sterling 15
Lancaster 14
Redwood City 14
Phoenix 13
Atlanta 11
Frankfurt am Main 11
Haiphong 11
Naples 11
Palermo 11
Amsterdam 10
Catania 10
Florence 10
Turku 10
Da Nang 9
Norwalk 9
Poplar 9
Redondo Beach 9
Tokyo 9
Brasília 8
Verona 8
Chennai 7
Denver 7
Des Moines 7
Falls Church 7
Rio de Janeiro 7
San Mateo 7
Tashkent 7
Toronto 7
Warsaw 7
Baku 6
Bari 6
Belo Horizonte 6
Brooklyn 6
Cape Town 6
Detroit 6
Dhaka 6
Dulles 6
Ferrara 6
Johannesburg 6
Montreal 6
Mumbai 6
Nanjing 6
Newark 6
Padova 6
Pittsburgh 6
Totale 6.518
Nome #
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 491
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 428
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 427
Use of Recombinant Factor IX and Thromboelastography in a Patient With Hemophilia B Undergoing Liver Transplantation: A Case Report 398
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 378
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 350
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 343
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 337
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 332
Achievements and unmet needs in the management of advanced ovarian cancer 329
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 313
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 305
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 303
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 301
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 288
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 262
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 259
Biomarkers predicting clinical benefit: fact or fiction? 253
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 250
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 247
Timing for starting second-line therapy in recurrent ovarian cancer 242
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 237
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 233
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 223
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 222
Tumori ginecologici 217
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 217
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER 199
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 191
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 182
Quantitative HER2 measurement and PI3K mutation profile in matched primary and metastatic breast cancer tissues. 180
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE 167
PREDICTIVE AND PROGNOSTIC ROLE OF P53 EXPRESSION IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY: A SINGLE INSTITUTION ANALYSIS 100
Totale 9.475
Categoria #
all - tutte 34.286
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.286


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 0 0 36
2021/2022539 9 86 57 12 11 23 27 13 64 45 121 71
2022/20231.047 97 98 58 76 71 103 13 62 403 11 29 26
2023/2024559 24 21 40 39 71 46 49 118 21 27 44 59
2024/20251.508 17 41 35 110 308 251 86 104 161 69 132 194
2025/20263.256 186 68 206 407 689 198 414 140 271 291 206 180
Totale 9.475